Bakk before remdesivir became a household name, the most discussed drug from Gilead Sciences was filgotinib, a treatment for inflammatory disease that was expected to provide billions of dollars in new revenue at a time when the biotech desperately needed it. Everything that came in danger Tuesday night.
The FDA rejected Gilead’s request to sell filgotinib as a treatment for rheumatoid arthritis, saying it would not reconsider until the company could provide more data on the effect of the drug on patients’ sperm counts. Gilead is conducting two studies to determine exactly that, but it will only have results next year.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days for free!
GET STARTED
What is it?
STAT Plus is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life sciences coverage and analysis. Our award-winning team covers news about Wall Street, policy developments in Washington, early breakthroughs in science and clinical trial outcomes, and limitation of health care in Silicon Valley and beyond.
What is included?
- Daily reporting and analysis
- The most comprehensive coverage of the sector from a powerhouse team of reporters
- Newsletters for subscribers
- Daily newsletters to keep you posted on the most important news of the day
- STAT + conversations
- Weekly Opportunities to Chat with Our Reporters and Leading Experts in Live Video Conversations
- Exclusive events in the sector
- Premium access to network subscribers only in the country
- The best reporters in the sector
- The most trusted and well-connected newsroom in the healthcare sector
- And so much more
- Exclusive interviews with leaders, profiles and premium tools, such as our CRISPR Trackr.
